PolyPeptide Group AG
🇬🇧XLON.0AAJUnited KingdomNot reported
Price£44.08-0.12 (-0.27%)
Latest anomalies
Very negative 9 detected in the last 120 days
- High: 7
- Medium: 1
- Low: 1
Volume: a spike above the 20-day average
Volume: a spike above the 20-day average
Volume: a spike above the 20-day average
Volume: a spike above the 20-day average
Overnight gap: a gap down from the prior close
Free with a Finzer account.
Profile
- United Kingdom
Identity
- Exchange
- London Stock Exchange . XLON
- Type
- Stock
- ISIN
- Not reported
- CUSIP
- Not reported
Company
- Employees
- 1,400
- Headquarters
- Baar, United Kingdom
- Website
- https://www.polypeptide.com
Market
- Shares outstanding
- 0
- Market cap
- £1.33B
Highlights
- Market cap
- £1.33B
- EPS LTM
- -€1.46
- P/E LTM
- -12.77
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- €485.17M+72.67%up year on year
- Net income
- -€48.21M-720.74%down year on year
- Gross margin
- 6.89%-62.77%down year on year
- Free cash flow
- €9M+109.62%up year on year
Latest news
News is not sourced for this exchange.
Business summary
PolyPeptide Group AG is listed on London Stock Exchange (United Kingdom) under the ticker 0AAJ. Its market capitalisation is £1.33B, as of . Across the 249 trading sessions to the shares traded between £22.05 and £50.00, and the last close of £44.08 sits 79% of the way up that range. The company is headquartered in Baar, United Kingdom, and employs about 1,400 people. This is the London Stock Exchange listing of PolyPeptide Group AG; its primary listing is PPGN on SIX Swiss Exchange.
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.